Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis

• Status: Completed
• Trial end date: 2020-12-30
• Target enrollment: 0
• Participant gender: All

Summary

This study was designed to analyze the prognosis and recurrence predictive factors of high risk patients (Clinical Risk Score≥3) of resectable colorectal liver metastasis.

The efficacy of perioperative chemotherapy plus cetuximab and chemotherapy alone was compared for these patients.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Cancer Hospital
• Collaborators: Beijing Municipal Administration of Hospitals; The First Affiliated Hospital of Kunming Medical College; West China Hospital; Zhejiang Cancer Hospital
• Treatments: Cetuximab; Fluorouracil; Leucovorin; Oxaliplatin

Criteria

Inclusion Criteria:

• good performance status

• pathologic diagnosis of colorectal cancer

• Rat sarcoma viral oncogene homolog(RAS) wild-type

• radiologic confirmation the resectability of liver metastases

• enough future liver remnant

• Clinical Risk Score≥3

• treatment naive

• extra-hepatic metastases could be resected completely, if exist

Exclusion Criteria:

• poor performance status, could not tolerate chemotherapy or operation

• other malignancy history or synchronously

• extra-hepatic metastases could not be resected completely, if exist

• received other treatment previously